Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Altria Group Inc (MO) Price & Performance

Medpace Holdings IncTrade
Altria Group IncTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Altria Group Inc — how do they compare? Medpace Holdings Inc trades at $532.91 (market cap $15.08B), while Altria Group Inc trades at $73.34 (market cap $124.67B). The key difference: Altria Group Inc is far larger — about 8.3× Medpace Holdings Inc's market cap, and Altria Group Inc pays a 5.68% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPMO
Market Cap
$15.08B$124.67B
Sector
TechnologyConsumer Staples
52-Week High
$620.59$74.66
52-Week Low
$308.88$54.72
Enterprise Value
$14.55B$145.75B
Dividend Yield
5.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Altria Group Inc

Altria (MO) trades at $74.14, down slightly by 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 39.52% net income margin and consistent dividend payments, including a recent $1.06 dividend declared for July 2026. Revenue remains stable around $20.1B for 2025, though net income dipped to $6.95B from prior peaks. Analyst consensus is predominantly bullish with 16 buys and a $71.00 price target.

Outlook: MO offers a high-yield dividend appeal and defensive positioning amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Earnings beats in recent quarters provide support, though debt levels and competitive shifts in nicotine products warrant caution for long-term growth investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

Read more on MO